Foghorn Therapeutics Inc. (FHTX)

Market Cap	285.75M
Revenue (ttm)	25.52M
Net Income (ttm)	-91.22M
Shares Out	55.59M
EPS (ttm)	-1.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	402,103
Open	4.93
Previous Close	4.98
Day's Range	4.90 - 5.28
52-Week Range	2.70 - 10.25
Beta	3.10
Analysts	Strong Buy
Price Target	13.80 (+168.48%)
Earnings Date	Nov 4, 2024

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 23, 2020
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: FHTX
• Website: https://foghorntx.com

Financial Performance

In 2023, Foghorn Therapeutics's revenue was $34.16 million, an increase of 77.63% compared to the previous year's $19.23 million. Losses were -$98.43 million, -9.60% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for FHTX stock is "Strong Buy." The 12-month stock price forecast is $13.8, which is an increase of 168.48% from the latest price.

Price Target

$13.8

(168.48% upside)

Analyst Consensus: Strong Buy